Skip to main content
Equibles

Michael Yee

Analyst

UBS

Equibles does not estimate personal net worth.

About Michael Yee

Michael Yee is recorded as Analyst at UBS. Michael Yee has spoken on 22 earnings calls and 4 other investor events across 14 companies, most recently for Johnson & Johnson on October 13, 2026. Those appearances were for Biogen Inc. (BIIB), Vertex Pharmaceuticals Inc (VRTX), Moderna, Inc. (MRNA), Bristol Myers Squibb Co (BMY), Merck & Co., Inc. (MRK) and 9 other companies. The companies whose calls Michael Yee spoke on are classified in the Healthcare sector.

Michael Yee on recent calls

“For the questions, maybe two pipeline science questions. On IcoTide, obviously you have great data and psoriasis is a little bit lower than biologics, but great data.”
Analyst — UBS Securities, Johnson & Johnson Third Quarter 2026 Earnings Call ·
“On TL1A, two-part question, you had one positive Phase III in UC, but not a whole lot was said. So how do you think we should think about the profile in ulcerative colitis appreciated in the second studies coming?”
Analyst — UBS, Merck & Co., Inc. Q2 FY2026 Earnings Call ·
“Just thinking about the strength of this to go, I think, Tuanne, you mentioned there's a 70% compliance. How are you thinking about things that you could do to get it higher?”
Analyst — UBS, Gilead Sciences Q2 2026 Earnings Conference Call ·
“I guess the IGAN competitor data to your EGFR data is hot off the press, and it's out there on the tape, and you can see that the approved product has essentially a stabilization of EGFR, if not slightly above a baseline.”
Analyst — UBS, Vertex Pharmaceuticals Q2 2026 Conference Call ·

Affiliation history

  • UBS

    Analyst

    Source not stated

    Current

Company network

Recent activity

Show 14 earlier activities